Anebulo Pharmaceuticals Inc.
ANEB
We are a clinical-stage pharmaceutical company developing treatments for cannabis-induced toxicity, such as acute cannabis-induced toxicity in children, acute cannabinoid intoxication ( ACI ) and the broader landscape of acute cannabis-induced conditions. Our lead product candidate, selonabant (formerly ANEB-001), is intended to rapidly reverse the negative effects of cannabis-induced …
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$8M
▼ -3.5% YoY
Op. Margin
–
ROIC
-67.22%
▼ -3.1pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$6M
▲ +21.5% YoY
Net Debt
-$9M
Net Cash Position
Cash & Equiv.
$9M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ANEB
Anebulo Pharmaceuticals (ANEB) in two numbers
Questions about Anebulo Pharmaceuticals
Does Anebulo Pharmaceuticals (ANEB) pay a dividend?
No. Anebulo Pharmaceuticals (ANEB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Feb 2026 (period ending 31 Dec 2025), SEC. Price: last close 19 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ANEB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ANEB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.